NCT04034589: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive,HR-Positive Metastatic Breast Cancer

NCT04034589
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients who have never been treated with Herceptin/trastuzumab, chemotherapy or endocrine therapy; Patients who have not already received first-line treatment for metastatic disease
https://ClinicalTrials.gov/show/NCT04034589

Comments are closed.

Up ↑